Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF Summary
Why choose R&D Systems PD-L1 Protein, Fc chimera?
- Guaranteed Bioactivity and High Purity: Bioactivity tested by functional ELISA and purity determined by SDS-PAGE to be greater than 90%.
- Lot-to-Lot Consistency: Stringent QC testing performed on each lot to ensure consistent activity and purity.
- Bulk Quantities Available: Bulk up and save with large mass quantities to meet your research needs. Supply agreements available, partner with us. Please contact us.
- Most Respected, Most Cited Brand in Proteins: With over 35 years of providing the best recombinant proteins to the scientific community, R&D Systems continues to lead the industry in quality, activity, and purity.
Find the non-Fc, His-tagged PD-L1 protein here PD-L1 His
Visit Bio-Techne to explore other immune checkpoint proteins Immune Checkpoint Proteins
Product Specifications
Human PD-L1 (Phe19-Thr239) Accession # Q9NZQ7 |
DIEGRMD | Human IgG1 (Pro100-Lys330) |
N-terminus | C-terminus | |
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
156-B7
Formulation | Lyophilized from a 0.2 μm filtered solution in PBS and NaCl. |
Reconstitution | Reconstitute at 100 μg/mL in sterile PBS. |
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Scientific Data
![](https://aeroglobalimagesuat.blob.core.windows.net/images/datasheets/156-b7_recombinant-human-pd-l1-b7-h1-fc-chimera-protein-cf-sec-mals-35202385256..jpg)
Recombinant human B7-H1/Fc (Catalog # 156-B7) has a molecular weight (MW) of 135.0 kDa as analyzed by SEC-MALS, suggesting that this protein is a homodimer. MW may differ from predicted MW due to post-translational modifications (PTMs) present (i.e. Glycosylation).
![Graph showing bioactivity of Human PD-L1 protein (B7-H1 protein) Graph showing bioactivity of Human PD-L1 protein (B7-H1 protein)](https://aeroglobalimagesuat.blob.core.windows.net/images/datasheets/protein/PDL1_156B7_2664.jpg)
Recombinant Human PD-L1 / B7-H1 Fc Chimera (Catalog # 156-B7) inhibits anti-CD3 antibody-induced IL-2 secretion in human T lymphocytes. The ED50 for this effect is 0.075-0.75 µg/mL in the presence of Goat Anti-Human IgG Fc Polyclonal Antibody (Catalog # G-102-C).
Reconstitution Calculator
Background: PD-L1/B7-H1
PD-L1, also known as B7-H1, PDL1, is one of the ligands for PD-1 and plays a critical role in the regulation of T cell immunity (1-6). The PD-1:PD-L1 interaction initiates a negative signaling cascade in T cells leading to inhibition of T cell activation (2, 5, 7, 8). PD-L1 provides a molecular stop signal to the adaptive immune system helping to distinguish between self and foreign antigens. PD-L1 also plays a role in the development of immune tolerance by promoting T cell anergy (1, 5) and enhancing regulatory T cell development (8). In addition, PD-L1 favors the development of anti-inflammatory IL-10 and IL-22 producing dendritic cells (7, 9) and inhibits the development of Th17 cells (8). Many cancers exhibit upregulated PD-L1 protein expression, and several cancers with high levels of PD-L1 have been associated with increased tumor aggressiveness and poor prognosis. Using new therapeutics that block the PD-L1:PD-1 interaction has proven successful in the clinic for many cancer types and has sparked great interest in the field of cancer immunotherapy.
The PD-L1 protein is an approximately 65 kDa transmembrane glycoprotein belonging to the B7 family of immune regulatory molecules (10). Mature human PD-L1 protein consists of a 220 amino acid (aa) extracellular domain (ECD) with two immunoglobulin-like domains, a 21 aa transmembrane segment, and a 31 aa cytoplasmic domain (11). Within the ECD, human PD-L1 shares 73% and 74% aa sequence identity with mouse and rat B7-H1, respectively. Alternative splicing generates additional isoforms that either lack the first Ig-like domain or are truncated within the second Ig-like domain (12). PD-L1 is expressed on inflammatory-activated immune cells including macrophages, T cells, and B cells (10, 13, 14, 16) keratinocytes (9, 11), endothelial and intestinal epithelial cells (2, 9), as well as a variety of carcinomas and melanoma (12, 16).
- Tsushima, F. et al. (2007) Blood 110:180.
- Mazanet, M.M. and C.C.W. Hughes (2002) J. Immunol. 169:3581.
- Azuma, T. et al. (2008) Blood 111:3635.
- Butte, M.J. et al. (2008) Mol. Immunol. 45:3567.
- Park, J.-J. et al. (2010) Blood 116:1291.
- Ritprajak, P. et al. (2010) J. Immunol. 184:4918.
- Chen, L. et al. (2007) J. Immunol. 178:6634.
- Herold, M. et al. (2015) J. Immunol. 195:3584.
- Scandiuzzi, L. et al. (2014) Cell Rep. 6:625.
- Ceeraz, S. et al. (2013) Trends Immunol. 34:556.
- Dong, H. et al. (1999) Nat. Med. 5:1365.
- Frigola, X. et al. (2011) Clin. Cancer Res. 17:1915.
- Tamura, H. et al. (2001) Blood 97:1809.
- Kuang, D.-M. et al. (2014) J. Clin. Invest. 124:4657.
- Cao, Y. et al. (2010) Cancer Res. 71:1235.
- Dong, H. et al. (2002) Nat. Med. 8:793.
Citations for Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
24
Citations: Showing 1 - 10
Filter your results:
Filter by:
-
In vitro and in vivo studies of plant-produced Atezolizumab as a potential immunotherapeutic antibody
Authors: Rattanapisit, K;Bulaon, CJI;Strasser, R;Sun, H;Phoolcharoen, W;
Scientific reports
Species: Human
Sample Types: Recombinant Protein
Applications: ELISA Standard -
Active PD-L1 incorporation within HIV virions functionally impairs T follicular helper cells
Authors: O Munoz, R Banga, R Schelling, FA Procopio, A Mastrangel, P Nortier, K Ohmiti, J Daraspe, M Cavassini, C Fenwick, L Perez, M Perreau
PloS Pathogens, 2022-07-05;18(7):e1010673.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
High mobility group protein B1 decreases surface localization of PD-1 to augment T-cell activation
Authors: Q Gao, S Wang, F Li, J Lian, S Cheng, D Yue, Z Zhang, S Liu, F Ren, D Zhang, S Wang, L Wang, Y Zhang
Cancer Immunology Research, 2022-07-01;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors
Authors: AP Curnock, G Bossi, J Kumaran, LJ Bawden, R Figueiredo, R Tawar, K Wiseman, E Henderson, SJ Hoong, V Gonzalez, H Ghadbane, DEO Knight, R O'Dwyer, DX Overton, CM Lucato, NMG Smith, CR Reis, K Page, LM Whaley, ML McCully, S Hearty, TM Mahon, P Weber
JCI Insight, 2021-10-22;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Oral immune dysfunction is associated with the expansion of FOXP3+PD-1+Amphiregulin+ T cells during HIV infection
Authors: N Bhaskaran, E Schneider, F Faddoul, A Paes da Si, R Asaad, A Talla, N Greenspan, AD Levine, D McDonald, J Karn, MM Lederman, P Pandiyan
Nature Communications, 2021-08-26;12(1):5143.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Protein detection in blood with single-molecule imaging
Authors: CP Mao, SC Wang, YP Su, SH Tseng, L He, AA Wu, RBS Roden, J Xiao, CF Hung
Science Advances, 2021-08-11;7(33):.
Species: Human
Sample Types: Reference Standard
-
Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child
Authors: M Ogishi, R Yang, C Aytekin, D Langlais, M Bourgey, T Khan, FA Ali, M Rahman, OM Delmonte, M Chrabieh, P Zhang, C Gruber, SJ Pelham, AN Spaan, J Rosain, WT Lei, S Drutman, MD Hellmann, MK Callahan, M Adamow, P Wong, JD Wolchok, G Rao, CS Ma, Y Nakajima, T Yaguchi, K Chamoto, SC Williams, JF Emile, F Rozenberg, MS Glickman, F Rapaport, G Kerner, G Allington, I Tezcan, D Cagdas, FO Hosnut, F Dogu, A Ikinciogul, VK Rao, L Kainulaine, V Béziat, J Bustamante, S Vilarinho, RP Lifton, B Boisson, L Abel, D Bogunovic, N Marr, LD Notarangel, SG Tangye, T Honjo, P Gros, S Boisson-Du, JL Casanova
Nature Medicine, 2021-06-28;0(0):.
Species: Human
Sample Types: Recombinant Protein
Applications: Bioassay -
Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments
Authors: C Vetrei, M Passariell, G Froechlich, R Rapuano Le, N Zambrano, C De Lorenzo
Cancers, 2021-06-08;13(12):.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2)
Authors: J Huetter, U Gritzan, I Gutcher, WD Doecke, MV Luetke-Eve, S Golfier, HG Roider, AL Frisk, J Hunter, A Pow, A Drake, Z Levine, O Levy, M Azulay, I Barbiro, G Cojocaru, I Vaknin, B Kreft, L Roese
Cancer Immunol Res, 2020-04-20;8(7):895-911.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Targeting glycosylated PD-1 induces potent anti-tumor immunity
Authors: L Sun, CW Li, EM Chung, R Yang, YS Kim, AH Park, YJ Lai, Y Yang, YH Wang, J Liu, Y Qiu, KH Khoo, J Yao, JL Hsu, JH Cha, LC Chan, JM Hsu, HH Lee, SS Yoo, MC Hung
Cancer Res., 2020-03-10;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries
Authors: B Cembrola, V Ruzza, F Troise, ML Esposito, E Sasso, V Cafaro, M Passariell, F Visconte, M Raia, L Del Vecchi, AM D'Alise, R Cortese, E Scarselli, N Zambrano, C De Lorenzo, A Nicosia
Biomed Res Int, 2019-12-28;2019(0):6051870.
Species: Yeast, Yeast - Saccharomyces cerevisiae
Sample Types: Whole Cell
Applications: Binding Assay -
LXR-inverse agonism stimulates immune-mediated tumor destruction by enhancing CD8 T-cell activity in triple negative breast cancer
Authors: KJ Carpenter, AC Valfort, N Steinauer, A Chatterjee, S Abuirqeba, S Majidi, M Sengupta, RJ Di Paolo, LP Shornick, J Zhang, CA Flaveny
Sci Rep, 2019-12-20;9(1):19530.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity
Authors: W Fu, C Lei, S Liu, Y Cui, C Wang, K Qian, T Li, Y Shen, X Fan, F Lin, M Ding, M Pan, X Ye, Y Yang, S Hu
Nat Commun, 2019-09-25;10(1):4355.
Species: Human
Sample Types: Whole Cells
Applications: CAR-T (Bioassay) -
Integrating SpyCatcher/SpyTag covalent fusion technology into phage display workflows for rapid antibody discovery
Authors: JK Fierle, J Abram-Sali, M Brioschi, M deTiani, G Coukos, SM Dunn
Sci Rep, 2019-09-06;9(1):12815.
Species: Human
Sample Types: Recombinant Protein
Applications: Bioassay -
Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients
Authors: A Osa, T Uenami, S Koyama, K Fujimoto, D Okuzaki, T Takimoto, H Hirata, Y Yano, S Yokota, Y Kinehara, Y Naito, T Otsuka, M Kanazu, M Kuroyama, M Hamaguchi, T Koba, Y Futami, M Ishijima, Y Suga, Y Akazawa, H Machiyama, K Iwahori, H Takamatsu, I Nagatomo, Y Takeda, H Kida, EA Akbay, PS Hammerman, KK Wong, G Dranoff, M Mori, T Kijima, A Kumanogoh
JCI Insight, 2018-10-04;3(19):.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Evaluation of Prognostic Immune Signatures in Patients with Breast, Colorectal and Pancreatic Cancer Receiving Chemotherapy
Authors: UM Vogl, L Öhler, M Rasic, JM Frischer, M Modak, J Stöckl
Anticancer Res., 2017-04-01;37(4):1947-1955.
Applications: ELISA (Standard) -
Characterization of the anti-PD-1 antibody REGN2810 and its antitumor activity in human PD-1 knock-in mice
Authors: E Burova, A Hermann, J Waite, T Potocky, V Lai, S Hong, M Liu, O Allbritton, A Woodruff, Q Wu, A D'Orvillie, E Garnova, A Rafique, W Poueymirou, J Martin, T Huang, D Skokos, J Kantrowitz, J Popke, M Mohrs, D MacDonald, E Ioffe, W Olson, I Lowy, A Murphy, G Thurston
Mol. Cancer Ther, 2017-03-06;0(0):.
Applications: Bioassay -
B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8(+) T cells
Sci Rep, 2016-11-08;6(0):36722.
Species: Human
Sample Types: Protein
Applications: ELISA (Standard) -
Tumor-infiltrating Tim-3(+) T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk
Authors: Robert L Ferris
Oncoimmunology, 2016-09-22;5(10):e1200778.
Applications: Bioassay -
PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment.
Authors: Li J, Jie H, Lei Y, Gildener-Leapman N, Trivedi S, Green T, Kane L, Ferris R
Cancer Res, 2014-12-05;75(3):508-18.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Soluble co-signaling molecules predict long-term graft outcome in kidney-transplanted patients.
Authors: Melendreras S, Martinez-Camblor P, Menendez A, Bravo-Mendoza C, Gonzalez-Vidal A, Coto E, Diaz-Corte C, Ruiz-Ortega M, Lopez-Larrea C, Suarez-Alvarez B
PLoS ONE, 2014-12-05;9(12):e113396.
Species: Human
Sample Types: Serum
Applications: ELISA (Standard) -
IDO-independent suppression of T cell effector function by IFN-gamma-licensed human mesenchymal stromal cells.
Authors: Chinnadurai R, Copland I, Patel S, Galipeau J
J Immunol, 2014-01-08;192(4):1491-501.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.
Authors: Steidl C, Shah SP, Woolcock BW
Nature, 2011-03-02;471(7338):377-81.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis.
Authors: Wan B, Nie H, Liu A, Feng G, He D, Xu R, Zhang Q, Dong C, Zhang JZ
J. Immunol., 2006-12-15;177(12):8844-50.
Species: Human
Sample Types: N/A, Whole Cells
Applications: Bioassay, ELISA (Standard)
FAQs
-
What is the pI (Isoelectric Point) of Recombinant Human PD-L1/B7-H1 Fc Chimera Protein (Catalog # 156-B7)?
The calculated pI for Recombinant Human PD-L1/B7-H1 Fc Chimera Protein (Catalog # 156-B7) is 7.1.
-
Do you have a human IgG1 Fc region that would be a suitable negative control for the linker sequence and Fc region in Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF (Catalog # 156-B7)?
Yes, we offer Recombinant Human IgG1 Fc Protein, CF (Catalog # 110-HG), which contains the human IgG Fc region and linker sequence.
-
Has Recombinant Human PD-L1/B7-H1 Fc Chimera Protein (Catalog # 156-B7), been evaluated on primary cells?
Bioactivity of Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF (Catalog # 156-B7) is evaluated by its ability to inhibit anti-CD3 antibody induced IL-2 secretion in human T lymphocyte primary cells. The ED50 for this effect is 0.075-0.75 μg/mL. We recommend reviewing our list of publications under the Citations tab on the product-specific web page to find reported use of our products in similar experimental layouts.
-
What are the differences between Recombinant Human PD-L1/B7-H1 His-tag Protein, CF (Catalog # 9049-B7) and Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF (Catalog # 156-B7)?
Recombinant Human PD-L1/B7-H1 Protein, CF (Catalog # 9049-B7) consists of (Phe19-Thr239) from Accession # Q9NZQ7. It has a His tag but no Fc chimera. Activity for 9049-B7 is measured in a binding assay with Recombinant Human PD‑1 Fc Chimera (Catalog # 1086-PD). Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF (Catalog 156-B7) consists of the same region (Phe19-Thr239), but instead of a His tag, it has a linker region and an Fc chimera. Activity for 156-B7 is assessed in a cell-based assay measuring IL-2 production by human T lymphocytes.
Reviews for Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
Average Rating: 4.9 (Based on 21 Reviews)
Have you used Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
Reason for Rating: Tested binding of PDL1-Fc w/ PD-1 using Octet. KD ~1.5uM
HEK cells expressing mCherry alone (LEFT) or hPD-1 mCherry (RIGHT) were incubated with 0.25 ug of hPD-L1 hIgG1. Binding was monitored by flow cytometry using an anti-human 488 secondary antibody.
Reason for Rating: Binding observed.
SPR experiment